Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans

Verouhis, Dinos; Saleh, Nawzad; Settergren, Magnus; Sörensson, Peder; Gourine, AV; Pernow, John

doi:10.1016/j.ijcard.2018.09.061

Cited by 14 publications

(16 citation statements)

References 197 publications

(293 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, GLP‐1 infusion increases left ventricular contractility, stroke volume, and cardiac output in animal models of induced dilated cardiomyopathy 36 . All these data, together with the evidence of a role for GLP‐1 on post‐ischaemia recovery and myocardial viability, have suggested a potential benefit for GLP‐1RA in patients with T2DM and concomitant HF 37,38 …”

Section: Non‐insulin Antihyperglycaemic Medications With Potential Nementioning

confidence: 96%

“…36 All these data, together with the evidence of a role for GLP-1 on post-ischaemia recovery and myocardial viability, have suggested a potential benefit for GLP-1RA in patients with T2DM and concomitant HF. 37,38 Several CV outcome trials have evaluated efficacy and safety of GLP1-RA. The ELIXA trial randomized 6068 patients with T2DM and a recent acute coronary syndrome to lixisenatide vs. placebo.…”

Section: Sulfonylureasmentioning

confidence: 99%

See 1 more Smart Citation

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials

et al. 2020

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is highly prevalent in the general population and especially in patients with heart failure (HF). It is not only a risk factor for incident HF, but is also associated with worse outcomes in prevalent HF. Therefore, antihyperglycaemic management in patients at risk of or with established HF is of importance to reduce morbidity/mortality. Following revision of the drug approval process in 2008 by the Food and Drug Administration and European Medicines Agency, several cardiovascular outcome trials on antihyperglycaemic drugs have recently investigated HF endpoints. Signals of harm in terms of increased risk of HF have been identified for thiazolidinediones and the dipeptidyl peptidase 4 inhibitor saxagliptin, and therefore, these drugs are not currently recommended in HF. Sulfonylureas also have an unfavourable safety profile and should be avoided in patients at increased risk of/with HF. Observational studies have assessed the use of metformin in patients with HF, showing potential safety and potential survival/morbidity benefits. Overall use of glucagon-like peptide 1 receptor agonists has not been linked with any clear benefit in terms of HF outcomes. Sodium-glucose cotransporter protein 2 inhibitors (SGLT2i) have consistently shown to reduce risk of HF-related outcomes in T2DM with and without HF and are thus currently recommended to lower risk of HF hospitalization in T2DM. Recent findings from the DAPA-HF trial support the use of dapagliflozin in patients with HF with reduced ejection fraction and, should ongoing trials with empagliflozin, sotagliflozin, and canagliflozin prove efficacy, will pave the way for SGLT2i as HF treatment regardless of T2DM.

show abstract

Section: Non‐insulin Antihyperglycaemic Medications With Potential Nementioning

confidence: 96%

Section: Sulfonylureasmentioning

confidence: 99%

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…CHD is the main cause of myocardial ischemia. With the improvement of living standards, the prevalence of myocardial ischemia in China is increasing annually and it has become a frequently [17][18][19][20]. Treatments based on traditional Chinese medicine have shown potential applications in myocardial ischemia treatment, and this has been reported in many studies.…”

Section: Discussionmentioning

confidence: 99%

Xuan Bi Tong Yu Fang Promotes Angiogenesis via VEGF‐Notch1/Dll4 Pathway in Myocardial Ischemic Rats

Dong

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To investigate the effect of Xuan Bi Tong Yu Fang (XBTYF) on angiogenesis via the vascular endothelial growth factor- (VEGF-) Notch1/delta-like 4 (Dll4) pathway. Materials and Methods. Sixty Sprague-Dawley rats were randomly divided into six groups: control, sham-operated, myocardial ischemia model, and XBTYF treatment at 3.2, 1.6, and 0.8 g/kg. Electrocardiography was performed to evaluate the successful establishment of the model. Hematoxylin-eosin staining and transmission electron microscopy were carried out to observe the morphology and mitochondrial structure in myocardial cells, respectively. TUNEL staining was performed to assess the degree of cell apoptosis. The expression of VEGF-A, Notch1, Dll4, Bcl2, Bax, caspase 3, caspase 9, and cytochrome-c (Cyt-c) was observed by western blot. Results. XBTYF inhibited changes to the morphology and mitochondrial structure in cardiomyocyte and reduced cell apoptosis. Compared with the model group, XBTYF at all doses (3.2, 1.6, and 0.8 g/kg) reduced the expression of Notch1, Dll4, Bax, caspase 3, caspase 9, and Cyt-c, whereas expression of VEGF-A and Bcl2 was increased. Conclusion. XBTYF attenuated mitochondrial damage and cell apoptosis while promoting the angiogenesis of cardiomyocyte. The associated mechanism may be related to the VEGF-Notch1/Dll4 pathway.

show abstract

“…120 A recent study also confirmed that RIC can improve the endothelium-dependent vasodilatory function of brachial arteries in the forearm. 121 The effector of RIC may act on the whole body through blood circulation. Therefore, it is inferred that the effector produced by RIC may have the same effect on cerebrovascular endothelial cells, thereby affecting cerebrovascular reactivity and improving cerebral hemodynamics.…”

Section: Ric Can Affect the Function Of Vascular Endothelial Cellsmentioning

confidence: 99%

“…Glucagon-like peptide-1 is an endocrine hormone released by L cells of the small intestine under the regulation of the efferent activity of the vagus nerve. 121 It has been discovered that selective severing of the posterior gastric branch of the vagus nerve can eliminate the protective effect of RIC, and stimulation of this branch can induce the protective effect of RIC. Scientists thus believe that the circulating factors of RIC are generated and released into the systemic circulation by the internal organs innervated by the posterior gastric branch of the vagus nerve.…”

Section: Ric Can Affect the Nervous Systemmentioning

confidence: 99%

<p>Effects of Remote Ischemic Conditioning on Cerebral Hemodynamics in Ischemic Stroke</p>

Chen¹,

Yan²,

Jin³

et al. 2020

NDT

View full text Add to dashboard Cite

Ischemic stroke is one of the most common cerebrovascular diseases and is the leading cause of disability all over the world. It is well known that cerebral blood flow (CBF) is disturbed or even disrupted when ischemic stroke happens. The imbalance between demand and shortage of blood supply makes ischemic stroke take place or worsen. The search for treatments that can preserve CBF, especially during the acute phase of ischemic stroke, has become a research hotspot. Animal and clinical experiments have proven that remote ischemic conditioning (RIC) is a beneficial therapeutic strategy for the treatment of ischemic stroke. However, the mechanism by which RIC affects CBF has not been fully understood. This review aims to discuss several possible mechanisms of RIC on the cerebral hemodynamics in ischemic stroke, such as the improvement of cardiac function and collateral circulation of cerebral vessels, the protection of neurovascular units, the formation of gas molecules, the effect on the function of vascular endothelial cells and the nervous system. RIC has the potential to become a therapeutic treatment to improve CBF in ischemic stroke. Future studies are needed to highlight our understanding of RIC as well as accelerate its clinical translation.

show abstract

Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans

Cited by 14 publications

References 197 publications

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials

Xuan Bi Tong Yu Fang Promotes Angiogenesis via VEGF‐Notch1/Dll4 Pathway in Myocardial Ischemic Rats

<p>Effects of Remote Ischemic Conditioning on Cerebral Hemodynamics in Ischemic Stroke</p>

Contact Info

Product

Resources

About